Empagliflozin — Uses, Dosage, Side Effects & Safety

Drug class: SGLT2 inhibitor

At a glance: Empagliflozin is an SGLT2 inhibitor primarily indicated for the management of Type 2 Diabetes Mellitus and the reduction of cardiovascular risk in adults with established cardiovascular disease. It works by inhibiting glucose reabsorption in the kidneys, leading to increased glucose excretion. Common side effects include genitourinary infections. Patients should be monitored for renal function and volume status throughout treatment.

Overview

Empagliflozin is a prescription medication used to help lower blood sugar levels in adults with type 2 diabetes mellitus. It is also approved to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, and to treat heart failure with reduced ejection fraction. Empagliflozin works by helping your kidneys remove excess glucose (sugar) from your body through urine. This process helps lower blood sugar and may also contribute to weight loss and lower blood pressure. Key points for patients: Empagliflozin is not for use in people with type 1 diabetes or for treating diabetic ketoacidosis. It is usually taken once daily in the morning, with or without food. Always follow your healthcare provider's instructions and report any unusual symptoms, especially signs of dehydration or infection.

Clinical information

[{"title":"Mechanism of Action","content":"Empagliflozin selectively inhibits the sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubules, reducing reabsorption of filtered glucose and increasing urinary glucose excretion. This leads to decreased plasma glucose concentrations and a mild osmotic diuresis. "},{"title":"Detailed Pharmacokinetics","content":"Absorption: Rapidly absorbed after oral administration, with peak plasma concentrations (Tmax) at 1.5 hours. Bioavailability is approximately 78%. Distribution: Volume of distribution is about 73.8 L. Protein binding is high (~86%). Metabolism: Primarily metabolized via glucuronidation (UGT2B7, UGT1A3, UGT1A8, UGT1A9). Elimination: Terminal half-life is 10-13 hours. Excreted mainly in urine (54%) and feces (41%). "},{"title":"Clinical Contraindications & Precautions","content":"Contraindicated in patients with hypersensitivity to empagliflozin, severe renal impairment (eGFR "},{"title":"Dose Adjustments","content":"Renal: Not recommended if eGFR "},{"title":"Monitoring Parameters","content":"Monitor renal function (eGFR), blood glucose, blood pressure, signs of urinary/genital infections, and symptoms of ketoacidosis. Periodically assess volume status and electrolytes. "},{"title":"Advanced Clinica

Therapeutic uses

• Cardiovascular Disease
• Reduction of cardiovascular death risk in adults with type 2 diabetes and established cardiovascular disease
• Chronic kidney disease with risk of progression
• Heart failure with reduced or preserved ejection fraction
• Type 2 Diabetes Mellitus
• Type 2 diabetes mellitus glycemic control

Common side effects

• Urinary tract infections
• Genital yeast infections
• Increased urination
• Dehydration
• Ketoacidosis
• Kidney problems
• Fournier's gangrene

Drug interactions

• May require dose adjustment of concomitant insulin secretagogues
• Increased hypoglycemia risk when combined with insulin or sulfonylureas
• Diuretics may add to volume depletion and hypotension risk

Contraindications

• History of serious hypersensitivity to empagliflozin
• Type 1 diabetes mellitus
• Severe renal impairment or dialysis (per current eGFR-based labeling)

Missed dose

If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular schedule. Do not take two doses at once.

Overdose

If you take too much empagliflozin, seek emergency medical attention. Symptoms may include excessive urination, dehydration, low blood pressure, or risk of ketoacidosis. Supportive care and monitoring of fluid and electrolyte balance are recommended.

Storage

Store at room temperature (20°C to 25°C/68°F to 77°F), away from moisture and heat. Keep out of reach of children.

Precautions & warnings

Associated with a risk of diabetic ketoacidosis, which can occur even with near-normal blood glucose; monitor for nausea, vomiting, and abdominal pain and stop the medication if suspected. Increases risk of genital mycotic infections and volume depletion, particularly in older adults or those on diuretics. Rare but serious risk of necrotizing fasciitis of the perineum (Fournier's gangrene).

Pregnancy

Not recommended during pregnancy, particularly in the second and third trimesters, due to potential effects on fetal kidney development.

Key safety information

• Risk of urinary tract infections
• Potential for dehydration and hypotension

Clinical Pearls

• May increase risk of diabetic ketoacidosis, even with normal blood sugar.
• Can cause serious urinary tract or genital infections.
• May lead to dehydration and low blood pressure, especially in elderly or those on diuretics.
• Not recommended in severe kidney impairment or dialysis.
• Monitor for signs of Fournier’s gangrene (rare but serious infection).
• Avoid becoming dehydrated; drink plenty of fluids unless otherwise directed.
• Avoid alcohol, which can increase the risk of low blood sugar and dehydration.
• Avoid taking other medications that may increase the risk of kidney problems without consulting your doctor.

Frequently Asked Questions about Empagliflozin

What is empagliflozin used for?

Empagliflozin is used to lower blood sugar in adults with type 2 diabetes, reduce the risk of cardiovascular death in those with type 2 diabetes and heart disease, and treat heart failure with reduced ejection fraction.

How does empagliflozin work?

It works by blocking a protein in the kidneys (SGLT2), causing excess sugar to be removed from the body through urine.

Can empagliflozin cause low blood sugar?

Empagliflozin alone rarely causes low blood sugar, but the risk increases if taken with insulin or other diabetes medicines that lower blood sugar.

Is empagliflozin safe in kidney disease?

Empagliflozin is not recommended for people with severe kidney impairment (eGFR

What should I do if I develop signs of infection while taking empagliflozin?

Contact your healthcare provider promptly if you develop symptoms of urinary tract or genital infection, such as pain, burning, fever, or unusual discharge.

Can I take empagliflozin if I am pregnant or breastfeeding?

Empagliflozin is not recommended during pregnancy or breastfeeding. Discuss with your doctor if you are or plan to become pregnant.

Does empagliflozin help with weight loss?

Some people may experience modest weight loss while taking empagliflozin, as excess sugar is excreted in the urine.

Educational information only. Always consult a qualified healthcare professional before starting, stopping, or changing any medication.